The X protein of hepatitis B virus inhibits apoptosis in hepatoma cells through enhancing the methionine adenosyltransferase 2A gene expression and reducing S-adenosylmethionine production.
The X protein (HBx) of hepatitis B virus (HBV) is involved in the development of hepatocellular carcinoma (HCC), and methionine adenosyltransferase 2A (MAT2A) promotes the growth of liver cancer cells through altering S-adenosylmethionine homeostasis. Thus, we speculated that a link between HBx and MAT2A may contribute to HCC development. In this study, the effects of HBx on MAT2A expression and cell apoptosis were investigated, and the molecular mechanism by which HBx and MAT2A regulate tumorigenesis was evaluated. Results from immunohistochemistry analyses of 37 pairs of HBV-associated liver cancer tissues/corresponding peritumor tissues showed that HBx and MAT2A are highly expressed in most liver tumor tissues. Our in vitro results revealed that HBx activates MAT2A expression in a dose-dependent manner in hepatoma cells, and such regulation requires the cis-regulatory elements NF-κB and CREB on the MAT2A gene promoter. Electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) further demonstrated that HBx facilitates the binding of NF-κB and CREB to MAT2A gene promoter. In addition, overexpression of HBx or MAT2A inhibits cell apoptosis, whereas knockdown of MAT2A expression stimulates apoptosis in hepatoma cells. Furthermore, we demonstrated that HBx reduces MAT1A expression and AdoMet production but enhances MAT2β expression. Thus, we proposed that HBx activates MAT2A expression through NF-κB and CREB signaling pathways to reduce AdoMet production, inhibit hepatoma cell apoptosis, and perhaps enhance HCC development. These findings should provide new insights into our understanding how the molecular mechanisms underline the effects of HBV infection on the production of MAT2A and the development of HCC.
Department of General Surgery, Research Center of Digestive Diseases, Zhongnan Hospital, Wuhan 430071, China.
Quanyan
Q
Liu
Jiwei
J
Chen
Li
L
Liu
Jun
J
Zhang
Dongfeng
D
Wang
Lu
L
Ma
Yueming
Y
He
Yingle
Y
Liu
Zhisu
Z
Liu
Jianguo
J
Wu
D017209:Apoptosis; D006528:Carcinoma, Hepatocellular / Q000235:genetics* / Q000378:metabolism* / Q000821:virology; D004305:Dose-Response Relationship, Drug; D020869:Gene Expression Profiling; D015967:Gene Expression Regulation, Viral; D006515:Hepatitis B virus / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008113:Liver Neoplasms / Q000378:metabolism / Q000821:virology; D008716:Methionine Adenosyltransferase / Q000235:genetics* / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D010957:Plasmids / Q000378:metabolism; D011401:Promoter Regions, Genetic; D015398:Signal Transduction; D015534:Trans-Activators / Q000378:metabolism*; D054334:Viral Regulatory and Accessory Proteins
D016328:NF-kappa B; D015534:Trans-Activators; D054334:Viral Regulatory and Accessory Proteins; C057628:hepatitis B virus X protein; C527161:MAT2A protein, human; D008716:Methionine Adenosyltransferase
Arch Virol. 2005 Apr;150(4):721-41
15614436
Alcohol. 2005 Apr;35(3):227-34
16054984
J Biol Chem. 2007 Feb 16;282(7):4277-4287
17158882
FASEB J. 2001 May;15(7):1248-50
11344103
J Virol. 2006 May;80(9):4406-14
16611900
FASEB J. 2001 Jul;15(9):1507-16
11427482
Am J Physiol Gastrointest Liver Physiol. 2000 Jul;279(1):G178-85
10898761
Korean J Hepatol. 2007 Sep;13(3):320-40
17898549
J Biol Chem. 1953 Sep;204(1):403-16
13084611
J Immunol. 2007 Jan 1;178(1):503-10
17182590
J Virol. 2009 May;83(10):4718-31
19279112
J Lab Clin Med. 2006 Feb;147(2):58-66
16459163
Cancer Lett. 2007 Jul 18;252(2):157-70
17188425
Cancer Sci. 2006 Oct;97(10):977-83
16984372
Mol Cell Biol. 2004 Dec;24(23):10352-65
15542843
Gastroenterology. 1998 Feb;114(2):364-71
9453498
Front Biosci. 2007 Jan 01;12:234-45
17127296
J Nutr. 2002 Aug;132(8 Suppl):2377S-2381S
12163696
Hepatology. 1996 Nov;24(5):1090-7
8903381
FASEB J. 1996 Mar;10(4):471-80
8647346
J Biol Chem. 1999 Oct 15;274(42):29720-5
10514445
Anal Biochem. 1976 May 7;72:248-54
942051
Cancer Lett. 2007 Aug 8;253(1):43-52
17296261
J Huazhong Univ Sci Technolog Med Sci. 2007 Apr;27(2):167-9
17497287
Gastroenterology. 2008 Jan;134(1):281-91
18045590
J Gastroenterol Hepatol. 2008 Mar;23 Suppl 1:S73-7
18336669
J Pathol. 2006 Feb;208(3):372-80
16353167
Biochem Biophys Res Commun. 2008 Sep 5;373(4):643-7
18602370
J Biol Chem. 2003 May 30;278(22):19885-90
12660248
Hepatology. 2008 Feb;47(2):521-31
18041713
FASEB J. 2004 Feb;18(2):382-4
14688211
FASEB J. 2002 Jan;16(1):15-26
11772932
FASEB J. 2000 Dec;14(15):2511-8
11099469
J Biol Chem. 2003 Dec 19;278(51):50887-96
14530285
Annu Rev Med. 1994;45:297-323
8198385
Biochem Soc Trans. 2006 Apr;34(Pt 2):330-3
16545107
Front Biosci (Landmark Ed). 2010 Jan 01;15:12-24
20036802
Intervirology. 2008;51(1):50-8
18334850
Phytochemistry. 2006 Aug;67(15):1686-98
16766004
J Biol Chem. 2003 Aug 22;278(34):31745-55
12799372
Hepatology. 2002 Jun;35(6):1381-91
12029623
J Cell Physiol. 2007 Mar;210(3):766-73
17154373
J Exp Clin Cancer Res. 2008 Nov 21;27:72
19025580
Hepatol Res. 2007 May;37(5):376-88
17441811
Adv Cancer Res. 2009;103:75-109
19854353